Search Results
Your search for The ,The matches 34625 pages
Showing 9351 - 9400Surge of Patients With Advanced Cancer Expected Due to Delayed Diagnosis and Treatment During Pandemic
Pent up demand for cancer screenings, diagnostic workups, and treatments delayed or curtailed since the start of the pandemic is expected to result in a surge of patients—some with more advanced disease as a result of delays—seeking appointments with oncologists. “We are starting to see the...
Expert Point of View: Alexander Eggermont, MD, PhD
Formal discussant of CheckMate 915, Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands, suggested that the lower doses of ipilimumab used in the current study may explain the lack of effect on relapse-free survival. The...
Lombardi Comprehensive Cancer Center, Georgetown University Names Kieron Dunleavy, MD, to Leadership Positions in Hematology
Kieron Dunleavy, MD, was appointed Director of Hematology at the Lombardi Comprehensive Cancer Center, Georgetown University, in Washington, DC. He is now also Chief of the Lymphoma Program at Georgetown University. Dr. Dunleavy joined Lombardi/Georgetown earlier this year. He is former Professor...
Comparing Nivolumab Plus Ipilimumab vs Nivolumab Alone in Resected Stage III to IV Melanoma
The addition of ipilimumab to nivolumab failed to improve outcomes compared with nivolumab alone as adjuvant therapy for resected melanoma, according to the results of the CheckMate 915 trial, presented at the virtual edition of the American Association for Cancer Research (AACR) Annual Meeting...
FDA Approves Nivolumab in Combination With Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma
On April 16, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. CheckMate 649 The...
Roswell Park Is First Site in Region Named a Resource for Patients With Rare Genetic Disease
Living with a genetic disorder that calls for regular monitoring, appropriate treatment, and emotional support calls for a multidisciplinary team that works together to coordinate patient care. Those diagnosed with von Hippel-Lindau (VHL) disease have a resource for complete and coordinated care in ...
AACR Inaugurates New Leadership at Virtual AACR Annual Business Meeting 2021
The American Association for Cancer Research (AACR) welcomed David A. Tuveson, MD, PhD, FAACR, as President of the organization for 2021–2022. He was inaugurated during the AACR Annual Business Meeting, held virtually on April 12. Dr. Tuveson is Director of the Cold Spring Harbor Laboratory Cancer...
Cannabis
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this article, Nirupa Raghunathan, MD, and Jyothirmai Gubili, MS, focus on the increasing use...
Expert Point of View: Peter Martin, MD
“With current therapies, the median survival for people with follicular lymphoma [FL] is about 20 years. Most people with FL will live as long as the general population, as it is a disease of morbidity more than mortality. That said, there is still room for improvement,” said formal CHRONOS-3...
CHRONOS-3: Addition of Copanlisib to Rituximab Extends Progression-Free Survival in Relapsed Indolent NHL
The combination of the PI3K inhibitor copanlisib plus the monoclonal antibody rituximab reduced the risk of disease progression or death by 48% compared with placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (NHL), according to the results of the phase III CHRONOS-3...
City of Hope Renames Research Center as the Arthur Riggs Diabetes & Metabolism Research Institute
City of Hope has announced the renaming of its diabetes research center as the Arthur Riggs Diabetes & Metabolism Research Institute, in honor of its long-time director and research pioneer. Arthur Riggs, PhD, is known for scientific achievements that include developing the technology leading...
Expert Point of View: Caroline Robert, MD
This is the first randomized trial that is positive for overall survival in uveal melanoma, and I’m very excited about the results, which I consider seminal and practice-changing,” said formal discussant Caroline Robert, MD, of Gustave Roussy, Villejuif, France. “This is such a rare tumor, but it...
Dana-Farber Cancer Institute Opens New State-of-the-Art Location
Dana-Farber Cancer Instituterecently announced a major expansion with the opening of a hospital facility in Chestnut Hill, Massachusetts, to provide increased cancer care and outpatient services for adult patients in the region. The new 140,000–square foot, state-of-art outpatient facility is...
A Sense of Duty Shapes the Career of Medical Oncologist Aparna Parikh, MD
By way of her family lineage, Aparna Parikh, MD, seemed destined for a career in medicine. “Both of my parents are physicians, as well as my maternal grandfather. I have two other siblings, all of whom are in the medical field. Medicine has always been part of my life since childhood. My parents...
‘MethylationToActivity’: A Deep Learning Framework for Epigenetic Research
Scientists at St. Jude Children’s Research Hospital are using a type of machine learning to put a new twist on an established technique. The researchers created MethylationToActivity (M2A), a framework for using DNA methylation data to reveal promoter activity and gene expression. The results were...
Bispecific Antibody Platform: Early Data in Relapsed and Refractory Myeloma
“There was never a night or a problem that could defeat sunrise or hope.” —Bernard Williams To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting...
UCLA Team Receives $6 Million From NIH to Explore New Pancreatic Cancer Therapies
A team of researchers from the University of California at Los Angeles (UCLA) Jonsson Comprehensive Cancer Center has been awarded two research grants totaling $6 million from the National Institutes of Health (NIH) to identify new ways to treat pancreatic cancer. “Pancreatic cancer is one of the ...
New Director of Neuro-Oncology Named to Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey has appointed Michael E. Salacz, MD, as Director of its Neuro-Oncology Program. The Associate Professor of Medicine at Rutgers Robert Wood Johnson Medical School joins Rutgers Cancer Institute from the University of Kansas Medical Center, where he served as...
Frederick W. Alt, PhD, Honored With 2021 AACR Award for Lifetime Achievement in Cancer Research
The American Association for Cancer Research (AACR) is recognizing geneticist Frederick W. Alt, PhD, with the 18th AACR Award for Lifetime Achievement in Cancer Research. Dr. Alt is a Howard Hughes Medical Institute investigator, Director of the Program in Cellular and Molecular Medicine at Boston ...
Tebentafusp Shows Overall Survival Benefit in First-Line Treatment of Metastatic Uveal Melanoma
Treatment with tebentafusp—a novel bispecific fusion protein—reduced the risk of death from metastatic uveal melanoma by half, compared with available treatments, in a phase III study presented at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.1 This is the first...
Expert Point of View: Ursula Matulonis, MD, and Konstantin Zakashansky, MD
Perspectives on ARIEL4 were provided for The ASCO Post by the invited discussant Ursula Matulonis, MD, Professor of Medicine, Harvard Medical School, and Chief of Gynecologic Oncology and the Brock Wilson Family Chair at Dana-Farber Cancer Institute, Boston, and by Konstantin Zakashansky, MD,...
Phase III ARIEL4 Confirms Rucaparib’s Benefit in BRCA-Mutated Relapsed Ovarian Cancer
In patients with BRCA-mutated, advanced, relapsed ovarian cancer, treatment with the PARP (poly [ADP-ribose] polymerase) inhibitor rucaparib led to a significant improvement in progression-free survival compared with standard-of-care chemotherapy, according to results of the international phase III ...
Maryam Lustberg, MD, MPH, Accepts Leadership Roles at Smilow Cancer Hospital, Yale Cancer Center
Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as Associate Professor of Medicine (Medical Oncology). Dr. Lustberg joins Yale from...
Expert Point of View: Jhanelle E. Gray, MD
Formal discussant of the CheckMate 816 trial, Jhanelle E. Gray, MD, of Moffitt Cancer Center, Tampa, said that both neoadjuvant and adjuvant therapies have been shown to improve overall survival and relapse-free survival in non–small cell lung cancer (NSCLC). “Overall, neoadjuvant outcomes compare...
Squamous Cell Carcinoma of the Head and Neck: Current Status and Future Directions
Although head and neck cancers include multiple histologies and primary sites, squamous cell carcinomas (SCC) originating in the oropharynx, oral cavity, larynx, or hypopharynx are the most common. Today, we recognize several different types of head and neck diseases, primarily those that are human ...
CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response in Resectable NSCLC
Neoadjuvant chemotherapy with nivolumab plus platinum-doublet chemotherapy significantly improved pathologic complete response rates compared with chemotherapy alone in patients with resectable stage IB to IIIA non–small cell lung cancer (NSCLC), according to the results of the CheckMate 816 study...
Shared Risk Factors for Preventing Cancer and Cardiovascular Disease: The Evolving Focus of Cardio-oncology
Cardio-oncology represents the intersection of cancer and cardiovascular disease. Cancer therapies can result in cardiovascular complications, and some patients become less attentive to their chronic disease management after a diagnosis of cancer. As cancer patients are living longer, for some,...
Are Prevalent Cardiovascular Risk Factors Associated With Increased Risk of Subsequent Cancer?
In a study reported in JACC: CardioOncology, Emily S. Lau, MD, of the Cardiology Division, Department of Medicine, Massachusetts General Hospital, and colleagues found that the presence of cardiovascular disease (CVD) risk factors was significantly associated with an increased risk of future...
Virtual Meetings Are Here to Stay
In 2020, the 8th Annual Beirut Breast Cancer Conference (BBCC) was our last in-person meeting. The first cases of COVID-19 started in Lebanon around the end of February 2020, and the pandemic continues into its second year, with waves of rising cases following superspreader events and other likely...
Chênevert Family Brain Tumor Center Launched at Yale
Yale School of Medicine recently announced a gift to establish the Chênevert Family Brain Tumor Center at Yale Cancer Center. The Center will be a leading institution in worldwide neuro-oncology research, bringing groundbreaking solutions and hope to patients with brain tumors. The gift will...
First-Line Pembrolizumab Plus Chemotherapy in PD-L1–Positive Locally Recurrent Triple-Negative Breast Cancer
As reported in The Lancet by Javier Cortes, MD, of the International Breast Cancer Center, Quiron Group, Madrid and Barcelona, and colleagues, the second interim analysis of the phase III -KEYNOTE-355 trial has shown that the addition of pembrolizumab to chemotherapy improved progression-free...
John Marshall, MD, and Liza Marshall: When Cancer Strikes an Oncologist’s Family
John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a breast cancer survivor, talk about the impact of her diagnosis, how it changed their view of cancer care and the way clinicians communicate, and why their memoir has an important message.
Dr. John and Liza Marshall on Their New Book Off Our Chests: A Candid Tour Through the World of Cancer
This week, The ASCO Post sat down with Dr. John Marshall, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a former lawyer, active advocate for patients with cancer, and a breast cancer survivor. The Marshalls are the coauthors of a new book entitled Off Our...
Expert Point of View: Ezra E.W. Cohen, MD
Formal discussant of the FOENIX-CCA2 trial, Ezra E.W. Cohen, MD, of the University of California San Diego and Moores Cancer Center, was encouraged by the findings with highly selective targeted agents such as futibatinib and emphasized the importance of molecular profiling. “The molecular...
Phase II Trial Reports Anticancer Activity With Novel FGFR Inhibitor in Advanced Intrahepatic Cholangiocarcinoma
Futibatinib—a selective, fibroblast growth factor receptor (FGFR) inhibitor—demonstrated anticancer activity in patients with advanced intrahepatic cholangiocarcinoma and FGFR2 fusions or rearrangements. These findings are based on the primary results of the phase II FOENIX-CCA2 trial, which were...
Study Explores Racial Disparities in Renal Cell Carcinoma by Stage and Mortality
Research recently published by Valencia et al in the journal Cancers found that advanced-stage kidney cancer is more common in Hispanic American and Native American patients than in non-Hispanic White patients. Using data from the National Cancer Database and the Arizona Cancer Registry,...
Increased Loneliness Among Patients With Cancer During the COVID-19 Pandemic May Affect Symptom Burden
Loneliness and social isolation have been significant problems for the general population during the COVID-19 pandemic, but for patients with cancer, these issues were particularly acute, likely due to isolation and social distancing, according to a recent study published by Miaskowski et al in the ...
Relationship Between Germline BRCA Pathogenic Variants and Diminished Ovarian Reserve
In a study reported in the Journal of Clinical Oncology, Turan et al found the presence of germline BRCA pathogenic variants was associated with diminished ovarian reserve in young women, particularly in those diagnosed with breast cancer and those with BRCA1 variants. Study Details The individual...
Effect of Oral Chemotherapy Management Program on Capecitabine Toxicity
In a health system retrospective study reported in JCO Oncology Practice, Nhean et al found that implementation of an oral chemotherapy management program was associated with reduced rates of any-grade and severe capecitabine toxicity, less frequent toxicity-related emergency department visits and...
Prospective Study Explores Prostate Cancer and Treatment Outcomes By Race
A study designed to enroll an equal number of Black and White men with advanced prostate cancer confirmed key findings that have been evident in retrospective analyses and suggest potential new avenues for treating Black patients who disproportionately die of the disease. Researchers at Duke Cancer ...
AI System May Aid in Diagnosing Cancer of Unknown Primary
In 1% to 2% of cancer cases, the primary site of tumor origin cannot be determined. Because many modern cancer therapeutics target primary tumors, the prognosis for a cancer of unknown primary (CUP) is poor, with a median overall survival of 2.7 to 16 months. In order to receive a more specific...
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Posttransplant Cyclophosphamide
In a National Marrow Donor Program–sponsored phase II trial reported in the Journal of Clinical Oncology, Shaw et al found that a strategy of bone marrow hematopoietic cell transplant (HCT) from mismatched unrelated donors using posttransplant cyclophosphamide in patients with hematologic...
Early Triple-Negative Breast Cancer: Are Checkpoint Inhibitors Ready for Neoadjuvant or Adjuvant Use?
Recent clinical trials have been encouraging for the neoadjuvant or adjuvant use of immune checkpoint inhibitors in triple-negative breast cancer, but is this approach ready for the clinic? This question was addressed at PER’s Miami Breast Cancer Conference, held virtually this year, by Adam M....
IMagyn050 Trial: Addition of Atezolizumab to Bevacizumab and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer
As reported in the Journal of Clinical Oncology by Kathleen N. Moore, MD, and colleagues, the phase III IMagyn050/GOG 3015/ENGOT-OV39 trial has shown that the addition of atezolizumab to bevacizumab and chemotherapy did not significantly improve progression-free survival in patients with newly...
Karen E. Knudsen, MBA, PhD: The American Cancer Society’s First Female CEO Speaks Out
Karen E. Knudsen, MBA, PhD, of Sidney Kimmel Cancer Center at Jefferson Health, was recently appointed Chief Executive Officer of the American Cancer Society—the first female to head the organization in its 107-year history. Dr. Knudsen talks about the opportunities she sees ahead for the Society...
FDA Grants Accelerated Approval to Pembrolizumab Combination for HER2-Positive Gastric Cancer
On May 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) in combination with trastuzumab plus fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic...
Accuracy of Lung Cancer Risk Model in Diverse Populations
A commonly used risk prediction model does not accurately identify high-risk Black patients with lung cancer who could gain life-saving benefit from early screening—paving the way for improving screenings and guidelines. These findings were published in a research letter by Shusted et al in JAMA...
Expert Panel–Endorsed Quality Measures for End-of-Life Care for Children With Cancer
There is currently no consensus on what quality end-of-life care for children with cancer looks like, or how to measure and deliver it; however, investigators recently assembled an expert panel to help fill this void. In a study published by Emily Johnston, MD, MS, and colleagues in the journal...
The COVID-19 Pandemic and Cancer Screening Deficits in the United States
In a retrospective cohort study reported in JAMA Oncology, Ronald C. Chen, MD, MPH, and colleagues quantified cancer screening deficits in the United States associated with the COVID-19 pandemic and identified differences in deficits according to region and socioeconomic status. Study Details The...
Oncologists’ Views on Challenges in Opioid Prescribing for Patients With Cancer-Related Pain
In an interview study reported in JCO Oncology Practice, Yael Schenker, MD, MAS, and colleagues identified challenges and measures for improvement cited by oncologists in the safe and effective prescribing of opioids for their patients with cancer-related pain. Study Details The investigators...
